Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 8:12:20406207211019612.
doi: 10.1177/20406207211019612. eCollection 2021.

The role of carfilzomib in relapsed/refractory multiple myeloma

Andrew J Yee  1
Affiliations
Review

The role of carfilzomib in relapsed/refractory multiple myeloma

Andrew J Yee. Ther Adv Hematol. .

Abstract

Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.

Keywords: carfilzomib; multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Consulting for Adaptive Biotechnologies, Amgen, BMS, Celgene, GSK, Janssen, Karyopharm, Oncopeptides, Sanofi, Takeda. Research funding from Amgen, BMS, Celgene, Janssen.

References

    1. Kumar SK, Therneau TM, Gertz MA, et al.. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867–874. - PubMed
    1. Yong K, Delforge M, Driessen C, et al.. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol 2016; 175: 252–264. - PMC - PubMed
    1. Obeng EA, Carlson LM, Gutman DM, et al.. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107: 4907–4916. - PMC - PubMed
    1. Moreau P, Richardson PG, Cavo M, et al.. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947–959. - PMC - PubMed
    1. Richardson PG, Briemberg H, Jagannath S, et al.. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24: 3113–3120. - PubMed

LinkOut - more resources